These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29714124)

  • 1. Clinical application of pharmacogenetics in pain management.
    Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
    Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
    Smith DM; Weitzel KW; Elsey AR; Langaee T; Gong Y; Wake DT; Duong BQ; Hagen M; Harle CA; Mercado E; Nagoshi Y; Newsom K; Wright A; Rosenberg EI; Starostik P; Clare-Salzler MJ; Schmidt SO; Fillingim RB; Johnson JA; Cavallari LH
    Genet Med; 2019 Aug; 21(8):1842-1850. PubMed ID: 30670877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
    Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
    Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.
    Skaar TC; Myers RA; Fillingim RB; Callaghan JT; Cicali E; Eadon MT; Elwood EN; Ginsburg GS; Lynch S; Nguyen KA; Obeng AO; Park H; Pratt VM; Rosenman M; Sadeghpour A; Shuman S; Singh R; Tillman EM; Volpi S; Wiisanen K; Winterstein AG; Horowitz CR; Voora D; Orlando L; Chakraborty H; Van Driest S; Peterson JF; Cavallari LA; Johnson JA; Dexter PR;
    Clin Transl Sci; 2024 Aug; 17(8):e70005. PubMed ID: 39177194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.
    Yamamoto PA; Conchon Costa AC; Lauretti GR; de Moraes NV
    Pharmacogenomics; 2019 Aug; 20(13):971-982. PubMed ID: 31486733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
    Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
    Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.
    Fulton CR; Zang Y; Desta Z; Rosenman MB; Holmes AM; Decker BS; Zhang Y; T Callaghan J; Pratt VM; Levy KD; Gufford BT; Dexter PR; Skaar TC; Eadon MT
    Pharmacogenomics; 2019 Apr; 20(6):397-408. PubMed ID: 30784356
    [No Abstract]   [Full Text] [Related]  

  • 9. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
    Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
    Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
    Mosley SA; Hicks JK; Portman DG; Donovan KA; Gopalan P; Schmit J; Starr J; Silver N; Gong Y; Langaee T; Clare-Salzler M; Starostik P; Chang YD; Rajasekhara S; Smith JE; Soares HP; George TJ; McLeod HL; Cavallari LH
    Contemp Clin Trials; 2018 May; 68():7-13. PubMed ID: 29535047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codeine and opioid metabolism: implications and alternatives for pediatric pain management.
    Chidambaran V; Sadhasivam S; Mahmoud M
    Curr Opin Anaesthesiol; 2017 Jun; 30(3):349-356. PubMed ID: 28323671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
    Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
    Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids.
    Knisely MR; Carpenter JS; Draucker CB; Skaar T; Broome ME; Holmes AM; Von Ah D
    Appl Nurs Res; 2017 Dec; 38():107-110. PubMed ID: 29241501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing pharmacogenetics to advance precision medicine for opioids.
    Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
    Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
    Thomas CD; Parvataneni HK; Gray CF; Deen JT; Prieto HA; Pulido LF; Elsey AR; Elwood EN; Starostik P; Gong Y; Fillingim RB; Johnson JA; Cavallari LH
    Genet Med; 2021 Apr; 23(4):621-628. PubMed ID: 33420349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
    Ramsey LB; Prows CA; Chidambaran V; Sadhasivam S; Quinn CT; Teusink-Cross A; Tang Girdwood S; Dawson DB; Vinks AA; Glauser TA
    Am J Health Syst Pharm; 2023 Jun; 80(13):852-859. PubMed ID: 36715063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
    Zahari Z; Ismail R
    Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
    Ballester P; Muriel J; Peiró AM
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
    Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.